Pdac
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Pdac is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- A ternary association of KRas, EphA2 and integrins controls PDAC cell behaviour. · J Biol Chem · 2026-08-10
- Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis. · J Food Sci · 2026-09-01
- Survivin Promotes the Formation of a Microtubule-Based Glycolytic Hub · bioRxiv Cancer Biology · 2026-08-31
- The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror? · Future Oncol · 2026-08-28
- Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer · medRxiv Oncology · 2026-08-27
- Inositol Polyphosphate-4-Phosphatase Type II promotes gemcitabine resistance in pancreatic ductal adenocarcinoma cells via lysosomal exocytosis · bioRxiv Cancer Biology · 2026-08-24
What the reporting says
It shows up alongside KRAS (20), Pancreatic Cancer (19).
Two steps out: Colorectal Cancer (through KRAS, 20 shared stories on the weaker link); Egfr (through KRAS, 20 shared stories on the weaker link); G12d (through KRAS, 20 shared stories on the weaker link); Immunotherapy (through KRAS, 20 shared stories on the weaker link).
Tracked since Apr 8, with coverage on 22 separate days — concentrated in Pubmed Targeted and Oncology.